Division of Hematology, University of Utah Medical Center, Salt Lake City, UT 84132, USA.
Am J Hematol. 2012 Sep;87(9):898-902. doi: 10.1002/ajh.23254. Epub 2012 May 31.
The use of prothrombin complex concentrates (PCCs), a heterogeneous combination of coagulation factors and counterbalancing inhibitor components, has broadened in recent years beyond single-factor replacement in conditions such as hemophilia B, to encompass emergency reversal of anticoagulation secondary to oral vitamin K antagonists, ie, warfarin therapy. PCCs also have been studied in other bleeding disorders, such as surgery-related and trauma-related bleeding. This review provides an updated examination of the differences among PCC formulations, their potential role in the management of bleeding disorders, and the primary safety issues affecting their use. Am. J. Hematol. 2012. © 2012 Wiley Periodicals, Inc.
近年来，凝血酶原复合物浓缩物（PCC）的使用范围不断扩大，已超越血友病 B 等单一因素替代治疗，涵盖了口服维生素 K 拮抗剂（如华法林治疗）引起的抗凝作用逆转。PCC 也在其他出血性疾病中进行了研究，如与手术和创伤相关的出血。本文综述了 PCC 制剂之间的差异，以及它们在出血性疾病管理中的潜在作用，重点讨论了影响其使用的主要安全性问题。Am. J. Hematol. 2012. © 2012 Wiley Periodicals, Inc.
